



**NEW MEDICINE APPLICATIONS BROUGHT TO THE
BORDERS FORMULARY COMMITTEE (BFC)
AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC)
2020/21**

New Medicine Product/Device Endorsement Categories

A	Approved for general use - hospital and general practice	Green	Unrestricted General Use Used widely and in accordance with a respectable, responsible body of clinical opinion (e.g. BNF for children; SIGN/NICE recommendation; royal college guidelines)
B	Approved for specialist use only	Amber	General Use With Restrictions (Prescribers to be outlined) Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Local use has peer group support and reflects practice in other NHS Board areas. May require "shared care protocol". (include information here) Specific patient consent not normally required.
C	Approved for specialist initiation, with ongoing prescribing in general practice	Red	Specialist Use Only Supporting clinical evidence has been evaluated by NHS Borders ADTC/Formulary committee. Limited evidence of efficacy available. Rarely used or may have serious potential side effects requiring close supervision of treatment Specific patient consent indicated.
D	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)	Black	Not Approved for use
E	Not approved (reason given to applicant)		
F	No decision – further information required (listed here)		

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 8th APRIL 2020

NMA	Indication	Speciality	BFC Decision
Meeting Cancelled			

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 13th MAY 2020

NMA	Indication	Speciality	ADTC Decision
No applications			

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 10th JUNE 2020

NMA	Indication	Speciality	BFC Decision
Ustekinumab (Stelera)	Treatment of adult patients with moderately to severe active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies	Gastroenterology	Category B
Fampridine (Fampyra)	For the improvement of walking in patients with multiple sclerosis with walking disability (EDSS expanded disability status scale 4-7)	Neurology	Category B
Guanfacine	For attention deficit hyperactivity disorder (ADHD) in children aged 6 to 18 years	Paediatrics	Category B (third choice in BJF)

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 8th JULY 2020

NMA	Indication	Speciality	ADTC Decision
LAT Gel	Topical use in anaesthetisation for paediatric in Emergency Department	ED	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 19th AUGUST 2020

NMA	Indication	Speciality	BFC Decision
Benralizumab (Fasenra)	An add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β -agonists. SMC restriction: patients with blood eosinophils ≥ 150 cells/microlitre, and either ≥ 4 prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over the previous 6 months.	Respiratory	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 16th SEPTEMBER 2020

NMA	Indication	Speciality	ADTC Decision
Amantadine	Fatigue in multiple sclerosis	Neurology	Category C

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 21st OCTOBER 2020

NMA	Indication	Speciality	BFC Decision
Andexanet alfa	For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban)	Anticoagulation	Category B

(Ondexxya)	or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.		
Budesonide (Jorveza)	Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). SMC restriction: For patients unsuccessfully treated with proton pump inhibitors.	Gastroenterology	Category C
Meropenem / Vaborbactam (Vaborem)	Treatment of the following infections in adults; Complicated urinary tract infection (cUTI) including pyelonephritis; Complicated intra-abdominal infection (cIAI); Hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP).		Category B
Cinacalcet (Mimpara)	Specialist initiation in renal patients with secondary hyperparathyroidism or tertiary hyperparathyroidism, who have very uncontrolled plasma levels of intact parathyroid hormone (greater than 800pg/ml). That are refractory to standard therapy and in whom surgical parathyroidectomy is not suitable.	Dialysis	Category C
Insulin glargine/ lixisenatide (Suliqua)	In combination with metformin for the treatment of adults with type 2 diabetes mellitus (T2DM), to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.	Endocrinology	Category F – when info received - Category C
Erenumab (Aimovig)	Prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: patients with chronic migraine and in whom at least three prior prophylactic treatments have failed.	Neurology	Category B
Semaglutide (Rybelsus)	Treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise - As monotherapy when metformin is considered inappropriate due to intolerance or contraindications; In combination with other medicinal products for the treatment of diabetes. SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option	Endocrinology	Category A

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 18th NOVEMBER 2020

NMA	Indication	Speciality	ADTC Decision
No applications			

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 16th DECEMBER 2020

NMA	Indication	Speciality	BFC Decision
Canagliflozin	1st line Sodium-glucose co-transporter 2 (SGLT2) inhibitor for diabetic	Diabetes	Category A

(Invokana)	nephropathy in Type 2 diabetes.		
Cannabidiol oral solution (Epidyolex)	Epilepsy - for seizures associated with Lennox-Gastaut syndrome in conjunction with clobazam or Dravet syndrome in conjunction with clobazam in patients over 2 years of age who are inadequately controlled by other anti-epileptic medicines.	Paediatrics	Category B
FreeStyle Libre2 Sensor	Direct replacement for FreeStyle Libre1 with the same restrictions as at present.	Diabetes	Category C

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 20th JANUARY 2021

	Indication	Speciality	ADTC Decision
No applications			

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 24th FEBRUARY 2021

NMA	Indication	Speciality	BFC Decision
Remdesivir (Veklury)	Treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment.	ITU	Category B
Tocilizumab (ROActemra)	Treatment of adult patients admitted to ICU with COVID19 pneumonia	ITU	RED Category
Romozosumab (Evenity)	Treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).	Rheumatology	Category B

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 24th MARCH 2021

NMA	Indication	Speciality	ADTC Decision
No applications			